**Name of Journal:** *World Journal of Methodology*

**Manuscript NO:** 41209

**Manuscript Type:** EDITORIAL

**Microembolic signal detection by transcranial Doppler: Old method with a new indication**

Muengtaweepongsa S *et al*. Microembolic detection by TCD

Sombat Muengtaweepongsa, Charturong Tantibundhit

**Sombat Muengtaweepongsa, Charturong Tantibundhit,** Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand

**ORCID number:** Sombat Muengtaweepongsa (0000-0003-3715-4428); Charturong Tantibundhit (0000-0002-3889-7314).

**Author contributions:** Muengtaweepongsa S contributed to conception and design of the work, data collection, drafting and critical revision of the article, and gave final approval; Tantibundhit C contributed to data collection and drafting of the article.

**Conflict-of-interest statement:** The authors declare they have no conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** **Sombat Muengtaweepongsa, MD, MRCP, MSc, Associate Professor,** Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand. musombat@staff.tu.ac.th

**Telephone:** +66-86-9994208

**Fax:** +66-29-269793

**Received:** August 4, 2018

**Peer-review started:** August 5, 2018

**First decision:** August 24, 2018

**Revised:** September 30, 2018

**Accepted:** October 17, 2018

**Article in press:**

**Published online:**

**Abstract**

Transcranial Doppler (TCD) is useful for investigation of intracranial arterial blood flow and can be used to detect a real-time embolic signal. Unfortunately, artefacts can mimic the embolic signal, complicating interpretation and necessitating expert-level opinion to distinguish the two. Resolving this situation is critical to achieve improved accuracy and utility of TCD for patients with disrupted intracranial arterial blood flow, such as stroke victims. A common type of stroke encountered in the clinic is cryptogenic stroke (or stroke with undetermined etiology), and patent foramen ovale (PFO) has been associated with the condition. An early clinical trial of PFO closure effect on secondary stroke prevention failed to demonstrate any benefit for the therapy, and research into the PFO therapy generally diminished. However, the recent publication of large randomized control trials with demonstrated benefit of PFO closure for recurrent stroke prevention has rekindled the interest in PFO in patients with cryptogenic stroke. To confirm that emboli across the PFO can reach the brain, TCD should be applied to detect the air embolic signal after injection of agitated saline bubbles at the antecubital vein. In addition, the automated embolic signal detection method should further facilitate use of TCD for air embolic signal detection after the agitated saline bubbles injection in patients with cryptogenic stroke and PFO.

**Key words:** Cryptogenic stroke; Patent foramen ovale; Transcranial Doppler; Recurrent stroke; Patent foramen ovale closure; Brain ischemia; Real-time emboli

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Patent foramen ovale (PFO) is an emerging etiology of cryptogenic stroke, and PFO closure therapy has been shown to reduce the rate of recurrent stroke. Detection of the air embolic signal by transcranial Doppler (TCD) after injection of agitated saline bubbles at the antecubital vein will help to confirm the importance of PFO as the cause of a concurrent stroke. In addition, the automated embolic signal detection method should further facilitate use of TCD for air embolic signal detection after the agitated saline bubbles injection in patients with cryptogenic stroke and PFO.

Muengtaweepongsa S, Tantibundhit C. Microembolic signal detection by transcranial Doppler: Old method with a new indication. *World J Methodol* 2018; In press

**INTRODUCTION**

Transcranial Doppler (TCD) is a noninvasive method for evaluating blood flow velocities in intracranial arteries. The TCD instrument is also used to detect emboli in real time, as they emerge in the main intracranial circulation. In general, an embolic signal representing an embolus has some characteristics that are distinctive from the signal that represents normal blood flow. Specifically, the embolic signal is classified as high intensity transient signals (commonly referred to as “HITS”) lying on top of the Doppler signal, deflected through an angle of 180 degrees by red blood cells. However, artefacts, caused by a variety of situations (*e.g.,* probe motion, patient movement, and sound waves from the patient speaking) are sometimes detected as HITS. Distinguishing embolic signals from artefacts requires an expert-level evaluation of the morphology of the signals, resulting in a subjective finding[1,2]. The multigated method was developed to improve the objective differentiation between embolic signals and artefacts. This technique samples signals from different depths of a similar vessel to demonstrate the motion of the following embolus from proximal to distal (Figure 1); in contrast, an artefact shows no movement property but appears in all depths simultaneously (Figure 2)[3].

**CRYPTOGENIC STROKE AND PATENT FORAMEN OVALE**

Cryptogenic stroke is described as a cerebral infarct of unclear or undetermined etiology, according to the Trial of Org 10172 in Acute Stroke Treatment stroke-subtype categorization system (TOAST). The source of cryptogenic stroke remains unclear mainly because the episode itself is temporary or reversible, and the available forms of clinical investigation do not address all possible etiologies. It is also important to consider that there may be additional etiologies that have yet to be recognized[4]. The finding that more than one-third of reported cerebral infarcts are categorized as cryptogenic etiology highlights the need for technologies and procedures to better investigate them[5].

Patent foramen ovale (PFO) is a possible etiology of cryptogenic stroke, especially in young adults. Prevalence of PFO is considerable, with estimates as high as 25% for the overall population. Moreover, it has been reported that around 50% of cryptogenic stroke patients of age less than 55 have a PFO[6]. The consideration of PFO as an etiology of consecutive cryptogenic stroke has been controversial, however, since early clinical trials of PFO closure therapy did not show any benefit for prevention of recurrent stroke[7-9]. Moreover, due to this reported lack of benefit, a routine practice of investigating cryptogenic stroke patients for PFO was not included among the recommendations in standard guidelines[10].

Three recent large randomized control trials (*i.e.*, RESPECT[11], REDUCE[12] and CLOSURE[13]) demonstrated benefit of PFO closure for secondary stroke prevention in selected cases of patients with cryptogenic stroke[11-13]. Of the three, the RESPECT study had the longest follow-up time, at 6 years[11]. The REDUCE study showed the benefit of PFO closure therapy over antiplatelet therapy, at 3 years after treatment[12]. The CLOSURE study included high-risk PFO cases with an atrial septal aneurysm or large interatrial shunt[13]. Data on device-related atrial fibrillation was reported in the REDUCE[12,13] and CLOSURE[12,13] studies. Furthermore, other recent studies carried out as meta-analyses also confirmed the benefit of PFO closure for secondary stroke prevention[14,15]. Considering these studies and their findings collectively, the next step would be carrying out systematic investigation of the potential for routinely seeking PFO in patients with cryptogenic stroke, particularly since the PFO itself holds promise as a target of therapy.

**TCD FOR PATIENTS WITH CRYPTOGENIC STROKE AND PFO**

Echocardiography plays a major role in diagnosis of PFO. In some cases, the PFO is detectable with color flow Doppler imaging in the echocardiogram. In most cases, the agitated saline bubbles test is mandatory for the diagnosis of PFO. In this procedure, a bolus of agitated saline is injected into an antecubital vein, after which air bubbles appear in the right atrium. A positive PFO finding is indicated when the air bubbles appear in the left atrium within three cardiac cycles of their initial appearance in the right atrium. The mechanism underlying this finding is the Valsalva maneuver, which increases right atrial pressure and facilitates right-to-left shunting[16].

Use of TCD for detection of the air embolic signal after injection of agitated saline bubbles into an antecubital vein is an alternative procedure to confirm right-to-left shunting. Detection of an air embolic signal in intracranial arteries should affirm that an embolus from the heart is able to reach the brain and cause the ischemic lesions. With the new indication for PFO closure, the use of TCD for air embolic signal detection with agitated saline bubbles test will be increased. The number of air embolic signals may be related to the size of the PFO, and such would help to strengthen the interpretation of clinical significance for the shunting.

Furthermore, the automated embolic signal detection method should improve the differentiation between artefacts and real emboli, and allow for counting the number of emboli[17,18]. The sensitivity and specificity of the automated system for differentiation between real emboli and artefacts were demonstrated to be as high as those of experts’ opinions[17,18]. With this automated method, TCD for air embolic signal detection with agitated saline bubbles test should be more useful in patients with cryptogenic stroke with PFO. Moreover, the automated method may extend use of TCD for embolic signal detection in other indications, such as emboli detection during invasive cardiac or great vessels procedure and microembolic monitoring during the first 48 h after onset of stroke[19,20].

**REFERENCES**

1 **Purkayastha S**, Sorond F. Transcranial Doppler ultrasound: technique and application. *Semin Neurol* 2012; **32**: 411-420 [PMID: 23361485 DOI: 10.1055/s-0032-1331812]

2 **D'Andrea A**, Conte M, Cavallaro M, Scarafile R, Riegler L, Cocchia R, Pezzullo E, Carbone A, Natale F, Santoro G, Caso P, Russo MG, Bossone E, Calabrò R. Transcranial Doppler ultrasonography: From methodology to major clinical applications. *World J Cardiol* 2016; **8**: 383-400 [PMID: 27468332 DOI: 10.4330/wjc.v8.i7.383]

3 **Ringelstein EB**, Droste DW, Babikian VL, Evans DH, Grosset DG, Kaps M, Markus HS, Russell D, Siebler M. Consensus on microembolus detection by TCD. International Consensus Group on Microembolus Detection. *Stroke* 1998; **29**: 725-729 [PMID: 9506619 DOI: 10.1161/01.Str.29.3.725]

4 **Adams HP Jr**, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 1993; **24**: 35-41 [PMID: 7678184 DOI: 10.1161/01.STR.24.1.35]

5 **Weimar C**. Stroke of undetermined cause: workup and secondary prevention. *Curr Opin Neurol* 2016; **29**: 4-8 [PMID: 26641813 DOI: 10.1097/WCO.0000000000000280]

6 **Lamy C**, Giannesini C, Zuber M, Arquizan C, Meder JF, Trystram D, Coste J, Mas JL. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. *Stroke* 2002; **33**: 706-711 [PMID: 11872892 DOI: 10.1161/hs0302.104543]

7 **Carroll JD**, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. *N Engl J Med* 2013; **368**: 1092-1100 [PMID: 23514286 DOI: 10.1056/NEJMoa1301440]

8 **Furlan AJ**, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, Raizner A, Wechsler L; CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. *N Engl J Med* 2012; **366**: 991-999 [PMID: 22417252 DOI: 10.1056/NEJMoa1009639]

9 **Meier B**, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, Wahl A, Windecker S, Jüni P; PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. *N Engl J Med* 2013; **368**: 1083-1091 [PMID: 23514285 DOI: 10.1056/NEJMoa1211716]

10 **O'Gara PT**, Messe SR, Tuzcu EM, Catha G, Ring JC; American Heart Association; American Stroke Association; American College of Cardiology Foundation. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials. A science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. *J Am Coll Cardiol* 2009; **53**: 2014-2018 [PMID: 19460622 DOI: 10.1016/j.jacc.2009.04.001]

11 **Saver JL**, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. *N Engl J Med* 2017; **377**: 1022-1032 [PMID: 28902590 DOI: 10.1056/NEJMoa1610057]

12 **Søndergaard L**, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, Settergren M, Sjöstrand C, Roine RO, Hildick-Smith D, Spence JD, Thomassen L; Gore REDUCE Clinical Study Investigators. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. *N Engl J Med* 2017; **377**: 1033-1042 [PMID: 28902580 DOI: 10.1056/NEJMoa1707404]

13 **Mas JL**, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, Béjot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour JC, Zuber M, Favrole P, Pinel JF, Apoil M, Reiner P, Lefebvre C, Guérin P, Piot C, Rossi R, Dubois-Randé JL, Eicher JC, Meneveau N, Lusson JR, Bertrand B, Schleich JM, Godart F, Thambo JB, Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard JM, Chatellier G; CLOSE Investigators. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. *N Engl J Med* 2017; **377**: 1011-1021 [PMID: 28902593 DOI: 10.1056/NEJMoa1705915]

14 **Tsivgoulis G**, Katsanos AH, Mavridis D, Frogoudaki A, Vrettou AR, Ikonomidis I, Parissis J, Deftereos S, Karapanayiotides T, Palaiodimou L, Filippatou A, Perren F, Hadjigeorgiou G, Alexandrov AW, Mitsias PD, Alexandrov AV. Percutaneous patent foramen ovale closure for secondary stroke prevention: Network meta-analysis. *Neurology* 2018; **91**: e8-e18 [PMID: 29875217 DOI: 10.1212/WNL.0000000000005739]

15 **Vaduganathan M**, Qamar A, Gupta A, Bajaj N, Golwala HB, Pandey A, Bhatt DL. Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials. *Am J Med* 2018; **131**: 575-577 [PMID: 29229471 DOI: 10.1016/j.amjmed.2017.11.027]

16 **Schuchlenz HW**, Weihs W, Beitzke A, Stein JI, Gamillscheg A, Rehak P. Transesophageal echocardiography for quantifying size of patent foramen ovale in patients with cryptogenic cerebrovascular events. *Stroke* 2002; **33**: 293-296 [PMID: 11779927 DOI: 10.1161/hs0102.100883]

17 **Sombune P**, Phienphanich P, Muengtaweepongsa S, Ruamthanthong A, Tantibundhit C. Automated embolic signal detection using adaptive gain control and classification using ANFIS. *Conf Proc IEEE Eng Med Biol Soc* 2016; **2016**: 3825-3828 [PMID: 28269120 DOI: 10.1109/EMBC.2016.7591562]

18 **Sombune P**, Phienphanich P, Phuechpanpaisal S, Muengtaweepongsa S, Ruamthanthong A, Tantibundhit C. Automated embolic signal detection using Deep Convolutional Neural Network. *Conf Proc IEEE Eng Med Biol Soc* 2017; **2017**: 3365-3368 [PMID: 29060618 DOI: 10.1109/EMBC.2017.8037577]

19 **von Bary C**, Deneke T, Arentz T, Schade A, Lehrmann H, Schwab-Malek S, Fredersdorf S, Baldaranov D, Maier L, Schlachetzki F. Clinical Impact of the Microembolic Signal Burden During Catheter Ablation for Atrial Fibrillation: Just a Lot of Noise? *J Ultrasound Med* 2018; **37**: 1091-1101 [PMID: 29034496 DOI: 10.1002/jum.14447]

20 **Iguchi Y**, Kimura K, Kobayashi K, Ueno Y, Shibazaki K, Inoue T. Microembolic signals at 48 hours after stroke onset contribute to new ischaemia within a week. *J Neurol Neurosurg Psychiatry* 2008; **79**: 253-259 [PMID: 17846111 DOI: 10.1136/jnnp.2007.123414]

**P-Reviewer:** Ciccone MM, Sharma P, Vieyra JP, Weng CF **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Medical laboratory technology

**Country of origin:** Thailand

**Peer-review report classification**


Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0



**Figure 1 Embolic signal.** The NICOLET Pioneer transcranial Doppler 4040 Doppler Waveform Analyzer was used.



**Figure 2 Artefact.** The NICOLET Pioneer transcranial Doppler 4040 Doppler Waveform Analyzer was used.